AU2012257780B2 - Pharmaceutical combination for use in the treatment of diabetes type 2 - Google Patents

Pharmaceutical combination for use in the treatment of diabetes type 2 Download PDF

Info

Publication number
AU2012257780B2
AU2012257780B2 AU2012257780A AU2012257780A AU2012257780B2 AU 2012257780 B2 AU2012257780 B2 AU 2012257780B2 AU 2012257780 A AU2012257780 A AU 2012257780A AU 2012257780 A AU2012257780 A AU 2012257780A AU 2012257780 B2 AU2012257780 B2 AU 2012257780B2
Authority
AU
Australia
Prior art keywords
injection
hlt
lixisenatide
combined
morning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012257780A
Other languages
English (en)
Other versions
AU2012257780A1 (en
Inventor
Gabor Boka
Patrick Miossec
Louise Silvestre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2012257780A1 publication Critical patent/AU2012257780A1/en
Application granted granted Critical
Publication of AU2012257780B2 publication Critical patent/AU2012257780B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012257780A 2011-05-13 2012-05-11 Pharmaceutical combination for use in the treatment of diabetes type 2 Ceased AU2012257780B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166052.8 2011-05-13
EP11166052 2011-05-13
PCT/EP2012/058779 WO2012156312A1 (en) 2011-05-13 2012-05-11 Pharmaceutical combination for use in the treatment of diabetes type 2

Publications (2)

Publication Number Publication Date
AU2012257780A1 AU2012257780A1 (en) 2013-12-05
AU2012257780B2 true AU2012257780B2 (en) 2017-06-01

Family

ID=46052773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012257780A Ceased AU2012257780B2 (en) 2011-05-13 2012-05-11 Pharmaceutical combination for use in the treatment of diabetes type 2

Country Status (12)

Country Link
US (1) US20130040878A1 (https=)
EP (1) EP2709652A1 (https=)
JP (1) JP6005140B2 (https=)
KR (1) KR20140041553A (https=)
CN (2) CN109045283A (https=)
AR (1) AR086356A1 (https=)
AU (1) AU2012257780B2 (https=)
BR (1) BR112013029256A8 (https=)
CA (1) CA2835336A1 (https=)
MX (1) MX356728B (https=)
RU (2) RU2017129878A (https=)
WO (1) WO2012156312A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2014207748B2 (en) * 2013-01-17 2018-10-11 Vtv Therapeutics Llc Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016015851A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
JP2023528726A (ja) 2020-04-01 2023-07-06 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
PL2324853T3 (pl) * 2009-11-13 2016-01-29 Sanofi Aventis Deutschland Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"GLP-1 Agonist AVE0010 (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin." https://clinicaltrials.gov/archive/NCT00712673/2011_03_22 Retrieved online 26 May 2016. *
CAMPAS, C. et al. "AVE-0010 GLP-1 Receptor Agonist Treatment of Diabetes." Drugs of the Future 2008, 33(10): 838-840. *
RATNER, R.E. et al. "Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin." Diabet Med. 2010 Sep;27(9):1024-32. *

Also Published As

Publication number Publication date
MX2013013198A (es) 2014-02-20
CN103648519A (zh) 2014-03-19
BR112013029256A2 (pt) 2016-11-29
US20130040878A1 (en) 2013-02-14
WO2012156312A1 (en) 2012-11-22
EP2709652A1 (en) 2014-03-26
MX356728B (es) 2018-06-12
KR20140041553A (ko) 2014-04-04
CA2835336A1 (en) 2012-11-22
CN109045283A (zh) 2018-12-21
JP6005140B2 (ja) 2016-10-12
BR112013029256A8 (pt) 2018-01-16
RU2017129878A (ru) 2019-02-05
RU2013155480A (ru) 2015-06-20
AR086356A1 (es) 2013-12-04
JP2014518860A (ja) 2014-08-07

Similar Documents

Publication Publication Date Title
AU2012257780B2 (en) Pharmaceutical combination for use in the treatment of diabetes type 2
AU2012257780A1 (en) Pharmaceutical combination for use in the treatment of diabetes type 2
US20250134964A1 (en) Method for inducing weight loss in a type 2 diabetes mellitus patient
AU2012213435B2 (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20230028588A1 (en) Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AU2012257847B2 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
AU2012234180B2 (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
AU2012257847A1 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired